<DOC>
	<DOC>NCT02331433</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects</brief_title>
	<detailed_description>The study will consist of 2 parts: (1) a single dose in healthy adult volunteers, (2) effect of food upon pharmacokinetics of a single dose of APN1125 in healthy adult volunteers.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy males and females Aged 18 to 65 years, inclusive Body mass index (BMI) of 18 to 32kg/m^2 inclusive at Screening Nonsmoker or no tobacco/nicotine usage with 30 days of Screening Personal or family history of neurological, cardiovascular, renal, hepatic, metabolic, gastrointestinal or endocrine abnormalities Any clinical abnormality in cardiovascular (e.g., blood pressure) or electrocardiogram (ECG) parameters at Screening and checkin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>